2026-05-30T13:00:07Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/260252026-02-03T11:20:59Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc De los Santos-Jiménez, Juan author Rosales, Tracy author Ko, Bookyung author Campos-Sandoval, José Ángel author Alonso-Carrión, Francisco José author Márquez-Gómez, Javier author DeBerardinis, Ralph J author Mates-Sánchez, José Manuel author 2023-01-15 Glioblastoma multiforme is the most common primary brain tumor. Unfortunately, it is also one of the cancer types that has the worst morbidity and mortality ratios, so new targets and treatments need to be found. The metabolism of glutamine is fundamental for the proliferation of many tumor cells, including glioblastomas. Glutaminase isoenzyme GLS is one of the responsible enzymes for the pro-oncogenic pathways that induce metabolic reprogramming and leads to altered levels of some amino acids and other key intermediary metabolites in glioblastoma. Using the clinically approved GLS inhibitor CB-839 (Telaglenastat), we found significant changes in glutamine metabolism, including both the oxidative and reductive fates of Gln-derived alpha-ketoglutarate in the tricarboxylic acid cycle, in three glioblastoma cell lines. One of them, the T98G glioblastoma cell line, showed the greatest modification of metabolite levels involved in the de novo biosynthetic pathways for nucleotides, as well as a higher content of methylated and acetylated metabolites. De los Santos-Jiménez J, Rosales T, Ko B, Campos-Sandoval JA, Alonso FJ, Márquez J, DeBerardinis RJ, Matés JM. Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines. Cancers. 2023; 15(2):531. https://doi.org/10.3390/cancers15020531 https://hdl.handle.net/10630/26025 https://doi.org/10.3390/cancers15020531 Cancer Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines